Ann Surg Treat Res.  2014 Aug;87(2):61-65. 10.4174/astr.2014.87.2.61.

Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience

• Karabulut
• Ozbalci GS
• Kesicioglu T
• Tarim IA
• Lap G
• Kamali Polat A
• Karabicak
• Erzurumlu

• KMID: 1882832
• DOI: http://doi.org/10.4174/astr.2014.87.2.61

Abstract

PURPOSE
The aim of this study was to evaluate long-term outcome of the intraoperative and perioperative albendazole (ALB) treatment on the recurrence and/or secondary hydatidosis.
METHODS
One hundred and one patients with hepatic hydatidosis were treated intraoperatively and perioperatively with ALB, in addition to surgery. Perioperative ALB treatment was given in a dose of 12-15 mg/kg/day. The ALB treatment was started 13.27 +/- 14.34 days before the surgery, and it was continued for 4.39 +/- 3.11 months postoperatively. A total of 1.7 microg/mL of ALB solution was used as a protoscolidal agent. The follow-up period was 134.55 +/- 51.56 months.
RESULTS
Four patients died, with only one death was secondary to hydatid disease (cerebral eccinococcus). There was only one recurrence (1%) of hepatic hydatidosis. Early and late morbidity rates were 8.91% and 7.92%, respectively.
CONCLUSION
Our results suggest that intraoperative and perioperative ALB is effective for the prevention of hepatic hydatidosis recurrence and/or secondary hydatidosis.

Keyword

Albendazole; Hepatic echinococcosis; Recurrence

MeSH Terms

Albendazole*
Echinococcosis
Echinococcosis, Hepatic*
Follow-Up Studies
Humans
Recurrence
Albendazole